Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study
Published inLung cancer, vol. 172, p. 154-159
Publication date2022-10
First online date2022-08-28
Abstract
Keywords
- FGFR inhibitor
- SQCLC
- Carcinoma, Non-Small-Cell Lung / drug therapy
- Carcinoma, Non-Small-Cell Lung / genetics
- Carcinoma, Non-Small-Cell Lung / metabolism
- Carcinoma, Squamous Cell / drug therapy
- Humans
- Lung Neoplasms / drug therapy
- Lung Neoplasms / genetics
- Lung Neoplasms / metabolism
- Piperazines
- Protein Kinase Inhibitors / therapeutic use
- Pyrroles
- RNA, Messenger / genetics
- RNA, Messenger / metabolism
- Thiophenes
Affiliation entities
Research groups
Citation (ISO format)
ADDEO, Alfredo et al. Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. In: Lung cancer, 2022, vol. 172, p. 154–159. doi: 10.1016/j.lungcan.2022.08.016
Main files (1)
Article (Published version)
Secondary files (4)
Identifiers
- PID : unige:167315
- DOI : 10.1016/j.lungcan.2022.08.016
- PMID : 36099710
Journal ISSN0169-5002